Poolbeg Pharma (LON:POLB) Stock Price Down 3.2% – Should You Sell?

Poolbeg Pharma PLC (LON:POLB)’s stock price traded down 3.2% during mid-day trading on Thursday . The stock traded as low as GBX 4.30 and last traded at GBX 4.50. 1,183,818 shares were traded during trading, a decline of 7% from the average session volume of 1,268,475 shares. The stock had previously closed at GBX 4.65.

Analyst Ratings Changes

Separately, Shore Capital reissued a “house stock” rating on shares of Poolbeg Pharma in a research report on Thursday, November 20th.

Poolbeg Pharma Trading Down 3.2%

The company’s 50-day simple moving average is GBX 4.08 and its 200 day simple moving average is GBX 3.65. The stock has a market cap of £31.37 million, a P/E ratio of -3.95 and a beta of 2.11.

About Poolbeg Pharma

Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company’s lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity.